SynthesisBMC pediatrics2025
Assessing the efficacy of infliximab in promoting vascular and mucosal healing in immunoglobulin-resistant kawasaki disease: a meta-analysis.
Synthesis in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This meta-analysis investigates the efficacy of infliximab in reducing vascular damage, suppressing inflammation, and promoting mucosal healing in patients with immunoglobulin-resistant Kawasaki Disease (KD). A systematic literature search was conducted in line with PRISMA guidelines across databases (e.g., PubMed, Google Scholar) for studies published between, 2003-2023. While high-dose intravenous immunoglobulin remains the standard treatment for KD, a subset of patients exhibit resistance, necessitating alternative therapeutic strategies. Infliximab, a monoclonal antibody that targets tumor necrosis factor-alpha, presents a promising option for these challenging cases. By modulating the immune response and suppressing inflammation, Infliximab has the potential to alleviate vascular damage and enhance mucosal healing in patients unresponsive to conventional treatments. This study specifically focuses on the impact of Infliximab on healing of vascular damage, as indicated by clinical remission, mucosal healing, and changes in absolute neutrophil counts-a key marker of inflammation. Employing a proportional meta-analysis via the 'metafor' function in R, we analyzed data from 857 patients, including 403 events related to mucosal and vascular healing outcomes. Our findings reveal a significant improvement in these healing processes among KD patients treated with Infliximab (Proportion: 0.45, 95% CI: [0.42; 0.48], I² = 87%, p < 0.01), accompanied by a notable reduction in inflammation as evidenced by decreased absolute neutrophil counts (mean difference: 7.67). These results underscore the potential of Infliximab and similar biologic therapies to effectively address the unmet needs of patients with immunoglobulin-resistant KD, offering a viable pathway to mitigate inflammation and enhance mucosal and vascular healing outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.